We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

32 hedge funds and large institutions have $15.1M invested in DiaMedica Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

12,600% more call options, than puts

Call options by funds: $127K | Put options by funds: $1K

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

284% more capital invested

Capital invested by funds: $3.93M → $15.1M (+$11.2M)

28% more funds holding

Funds holding: 25 → 32 (+7)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

3.26% more ownership

Funds ownership: 9.7% → 12.96% (+3.3%)

Holders
32
Holders Change
+7
Holders Change %
+28%
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
7
Reduced
6
Closed
2
Calls
$127K
Puts
$1K
Net Calls
+$126K
Net Calls Change
+$113K

Top Buyers

Rank Fund Capital Flow
1
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Texas
+$789K
2
BL
Bleichroeder LP
New York
+$714K
3
EI
EAM Investors
California
+$657K
4
First Manhattan
First Manhattan
New York
+$303K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.1K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$99K
2
JAMONY
Jacob Asset Management of New York
California
-$85K
3
Citadel Advisors
Citadel Advisors
Florida
-$83.4K
4
Northern Trust
Northern Trust
Illinois
-$21K
5
Simplex Trading
Simplex Trading
Illinois
-$8.07K
Name Holding Trade Value Shares
Change 		Change in
Stake
CLG
1
Cooperman Leon G
$3.78M +$18.4K +7,580 +0.9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.38M – – –
PAPAIJV
3
Paragon Associates & Paragon Associates II Joint Venture
Texas
$1.4M +$789K +325,000 New
BL
4
Bleichroeder LP
New York
$1.27M +$714K +294,117 New
EI
5
EAM Investors
California
$1.17M +$657K +270,419 New
JAMONY
6
Jacob Asset Management of New York
California
$859K -$85K -35,000 -15%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$799K – – –
First Manhattan
8
First Manhattan
New York
$539K +$303K +124,744 New
Northern Trust
9
Northern Trust
Illinois
$355K -$21K -8,665 -10%
BlackRock
10
BlackRock
New York
$311K +$595 +245 +0.3%
State Street
11
State Street
Massachusetts
$288K – – –
Morgan Stanley
12
Morgan Stanley
New York
$247K -$214 -88 -0.2%
CFP
13
Catalyst Financial Partners
Massachusetts
$157K +$27.1K +11,157 +44%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$155K -$408 -168 -0.5%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$73.3K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$73.1K +$41.1K +16,923 New
Charles Schwab
17
Charles Schwab
California
$57.2K +$32.2K +13,251 New
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$42.3K +$18.4K +7,596 +345%
Citadel Advisors
19
Citadel Advisors
Florida
$34.2K -$83.4K -34,322 -81%
TRCT
20
Tower Research Capital (TRC)
New York
$27K +$617 +254 +4%
MPWT
21
MassMutual Private Wealth & Trust
Connecticut
$20.8K – – –
US Bancorp
22
US Bancorp
Minnesota
$18.7K – – –
TWC
23
TD Waterhouse Canada
Ontario, Canada
$8.11K – – –
LFA
24
Legend Financial Advisors
Pennsylvania
$4.32K – – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$3K +$192 +79 +10%
1
2

DMAC Hedge Fund Activity: Q2 2023 in Review

32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2023, worth a combined $15.1M — up 284% from $3.93M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new DMAC positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, opening a new position worth an estimated $789K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $99K sold.

  • 32 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2023, up from 25 in Q1 2023.
  • Funds reported $15.1M of DiaMedica Therapeutics stock for Q2 2023, up 284% quarter-over-quarter.
  • 9 funds opened new DiaMedica Therapeutics positions in Q2 2023 and 2 closed out, a net change of +7 holders.
  • The largest DiaMedica Therapeutics buyer in Q2 2023 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $789K added.
  • The largest DiaMedica Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $99K sold.

Based on aggregated 13F filings for Q2 2023.